Quantcast

Latest Tyrosine kinase inhibitors Stories

2012-03-19 16:58:18

Study outlines new method to test a tumor's resistance to an experimental therapy and pinpoint the genetic culprit before testing the drug in patients–providing a new path toward personalized medicine Drug resistance is a serious problem for cancer patients–over time, a therapy that was once providing some benefit simply stops working. Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) recently discovered how cancer cells develop resistance to a drug...

2012-02-27 07:26:30

A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that imatinib is the treatment of choice for these patients. Imatinib, a drug that blocks the protein made by a particular cancer-causing gene, has revolutionized the treatment and...

2012-02-21 12:29:08

MD Anderson research shows promise for patients suffering from chronic pain By reformulating the common cancer drug imatinib (Gleevec®), researchers have eliminated morphine tolerance in rats — an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center. Narcotics such as morphine are a mainstay of chronic pain treatment. Over time, tolerance to the pain-relieving...

2012-02-07 12:08:41

Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that the risk remains low, but should be taken into account by physicians and patients. The incidence of fatal complications was 1.5 percent in patients who received any of the three drugs, which block the vascular endothelial growth factor (VEGF) tyrosine kinase receptors...

2012-01-30 18:10:00

BioPlus Specialty Pharmacy selected as one of the limited number of specialty pharmacies with access to this advanced renal cell carcinoma second line therapy. Altamonte Springs, Florida (PRWEB) January 30, 2012 BioPlus Specialty Pharmacy (BioPlus), one of the nation´s leading specialty pharmacies, has launched axitinib (brand name: Inlyta, from Pfizer), a new cancer drug just approved by the FDA. BioPlus is pleased to be one of the small number of specialty pharmacies with access to...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related